CompletedNot Applicable

Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)

France11 participantsStarted 2020-04-30

Plain-language summary

Cases of chilblains have been reported with an unusual frequency in France in the context of the COronaVirus Infectious Disease 2019 (COVID-19) epidemic. Some of these cases have been linked to a virological status in favour of a recent Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. Chilblains are acral inflammatory lesion typically reactive to cold (primary form). There are secondary forms acquired during autoimmune connectivitis such as lupus chilblain or hereditary forms related to type I Interferonopathy. An interferon type I signature has been described in these secondary forms of frostbite but also during the cytokine storm of severe forms of CoV-2 SARS infection. If cases of frostbite are indeed secondary to an SARS-CoV-2 infection, comparative analysis of their immunopathological profiles could provide a better understanding of the inflammatory mechanisms during COVID-19.

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over the age of majority or a minor over 12 years of age accompanied by his/her legal representative * Benefiting from a Social Security scheme * Informed consent signed by the patient (if major) or by his legal representative (if minor) after clear, fair and appropriate information about the study. * Red and swollen lesions of the hands and/or feet evolving for more than 24 hours in the context of a COVID-19 epidemic. * PCR SARS-CoV-2 PCR on nasopharyngeal swab with results available, prior to the inclusion visit. * Absence of fever or respiratory signs suggestive of COVID-19 for at least 14 days Exclusion Criteria: * A person who does not benefit from a Social Security scheme or who does not benefit from it through a third party. * Patient who is subject to a judicial safeguard measure * Allergy to local anaesthetic products * Fever or respiratory signs suggestive of COVID-19 within 14 days

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.

Timeframe: 2 months

Trial details

NCT IDNCT04387955

SponsorPoitiers University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-07-30

View on ClinicalTrials.gov More COVID-19 trials